Thoracic Surgery, Niizashiki Chuo General Hospital, Saitama, Japan.
J Proteome Res. 2011 Jan 7;10(1):51-7. doi: 10.1021/pr100859b.
In Japan, rising costs have impacted the framework of maintaining an efficient and effective healthcare system. Today, urgent implementation of programs to address this need have led to a rebuilding of the entire approach of medical evaluation and clinical care. Recent developments in clinical proteomics based on mass spectrometry (MS) for identifying, sequencing, and quantifying disease-relevant protein biomarkers is a promising means for optimal drug prescription using biomarker diagnosis. We illustrate in this report our experience with lung cancer cases with various drug therapies evaluated with proteomics studies.
在日本，成本的上升已经影响到维持高效、有效的医疗保健系统的框架。如今，迫切需要实施相关计划来满足这一需求，这导致了对医疗评估和临床护理的整体方法的重建。基于质谱 (MS) 的临床蛋白质组学在识别、测序和定量与疾病相关的蛋白质生物标志物方面的最新进展，是使用生物标志物诊断进行最佳药物处方的一种很有前途的手段。在本报告中，我们举例说明了使用蛋白质组学研究评估各种药物治疗的肺癌病例的经验。
